Intriguingly, while PD-L1 and nivolumab exhibited discernible effects on osteoclastogenesis and osteoclast resorptive function in the control group, these phenomena were significantly more pronounced in the PJI cohort. The gene discussed is CD274; the disease is juvenile polyposis syndrome.